Association analysis between ICI efficacy data and multi-omics data (1) (IMAGE)
Caption
(A) Scatter plot depicting the association between the gene expression levels of NCAPG2 and the mOS data of cancer patients treated with ICIs. (B) Scatter plot illustrating the association between the gene expression levels of IFNG and the HROS data of cancer patients treated with ICIs. (C) Scatter plot showing the association between the gene expression levels of PDCD1 and HROS data of cancer patients treated with ICIs. (D) Scatter plot showing the association between the gene expression levels of LAG3 and HROS data of cancer patients treated with ICIs. (E) Scatter plot demonstrating the association between the mutation rate of the LRP1B and HROS data of cancer patients treated with ICIs. (F) Scatter plot demonstrating the association between the mutation rate of the PTPRT and mOS data of cancer patients treated with ICIs. The aforementioned tumor transcriptome data were sourced from the TCGA database, gene mutation data were obtained from the cBioPortal database, and tumor pathway-associated gene sets were downloaded from the MSigDB. The r and p values were calculated through Pearson and Spearman association analyses, respectively. Abbreviations: ICIs, immune checkpoint inhibitors; mOS, median overall survival; HROS, hazard ratios for overall survival; BER, base excision repair; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma.
Credit
Dr. Peng Luo
Usage Restrictions
Marked by the credited.
License
Original content